Generation Bio Co. (GBIO)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 17, 2025

$0.95

P/E Ratio

N/A

Market Cap

$63.32M

Jan 30, 2024Mar 8, 2024Apr 10, 2024May 20, 2024Jun 21, 2024Jul 24, 2024Aug 27, 2024Oct 2, 2024Nov 4, 2024Dec 5, 2024Jan 20, 2025$0.00$10.00
  • PVT
Description

Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

Metrics

Overview

  • HQCambridge, MA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerGBIO
  • Price$0.948+0.18%

Trading Information

  • Market cap$63.32M
  • Float63.43%
  • Average Daily Volume (1m)645,632
  • Average Daily Volume (3m)381,272
  • EPS-$2.19

Company

  • Revenue$18.58M
  • Rev growth (1yr)252.00%
  • Net income-$15.31M
  • Gross margin84.38%
  • EBITDA margin-205.65%
  • EBITDA-$15.54M
  • EV$73.85M
  • EV/Revenue3.97
  • P/EN/A
  • P/S3.40
  • P/B0.61
Documents